Aldagen, a biotechnology firm focused on regenerative medicine, has received a U.S. patent for “A Method of Isolating Stem Cells.”
Aldagen is the new name for the company formerly known as StemCo Biomedical.
The patent covers methods of isolating adult stem cells from various sources, including bone marrow. Aldagen holds other related patents.
“The issuance of this patent further strengthens our intellectual property around Aldagen’s unique method for isolating adult stem cells,” said Ed Field, chief executive officer of Aldagen. “We have already incorporated this technology into marketed products and are now testing therapeutic applications of our Aldesort product in human clinical trials.
In December, Aldagen announced that it had isolated adult human stem cells that could regenerate vascular function.
“Aldesort is the only product that yields a mixture of highly active stem cell types from human bone marrow without altering their activities,” he added. “We have begun an aggressive program of clinical studies to demonstrate the activity of these cell populations in different tissue repair indications.”